ALCON INC
corporate_fare Company Profile
ALCON INC (NYSE:ALC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for ALC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-20, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 5 rated 8 or above. Recent SEC coverage for ALC spans 6-K, 20-F.
Recent high-impact activity:
- Alcon Pays $550M for Neurotech, Adding Only FDA-Approved MacTel Therapy
- Alcon Wins FDA Approval for OTC Brytly Eye Drops
- Alcon Q2 Sales Climb 8% on New Product Launches; Core Margin and EPS Outlook Raised Despite $402M PowerVision Charge
- Alcon Q2 Sales Jump 8% to $2.8B, Raises Full-Year Margin and EPS Outlook
- Alcon Reports Strong Q1 Results, Raises 2026 EPS Outlook, and Authorizes New $1.5B Share Buyback
Financial Snapshot
Short Interest & Short Volume
10.86 days to coverFINRA reported short interest of 19,554,732 shares in ALC as of the October 15, 2026 settlement, a 9.4% increase from the prior period — about 10.9 days to cover at its recent average daily volume. On November 5, 2026, 59.4% of ALC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
ALC files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.